Could Eiger BioPharmaceuticals, Inc. (EIGR) Rise Even More? The Stock Had Another Big Increase Today

December 7, 2017 - By Adrian Mccoy

The stock of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) is a huge mover today! The stock increased 7.17% or $0.85 during the last trading session, reaching $12.7. About 113,946 shares traded or 99.40% up from the average. Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has declined 64.64% since December 7, 2016 and is downtrending. It has underperformed by 81.34% the S&P500.
The move comes after 8 months positive chart setup for the $133.56 million company. It was reported on Dec, 7 by We have $13.46 PT which if reached, will make NASDAQ:EIGR worth $8.01 million more.

Analysts await Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) to report earnings on March, 22. They expect $-1.29 earnings per share, up 15.69 % or $0.24 from last year’s $-1.53 per share. After $-1.10 actual earnings per share reported by Eiger BioPharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 17.27 % negative EPS growth.

More notable recent Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) news were published by: which released: “Eiger BioPharmaceuticals Inc.” on March 24, 2016, also with their article: “Eiger BioPharmaceuticals Closes Merger With Celladon” published on March 23, 2016, published: “Eiger Biopharmaceuticals: Can This $10 Biotech Stock Continue To Rally?” on July 18, 2017. More interesting news about Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) were released by: and their article: “Eiger BioPharmaceuticals: Another Cheap Bio-Catalyst Play” published on March 21, 2017 as well as‘s news article titled: “Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene …” with publication date: June 29, 2017.

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. The company has market cap of $133.56 million. The Company’s product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.